Donovan Joanne M. 4

4 · Edgewise Therapeutics, Inc. · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

Edgewise (EWTX) CMO Joanne Donovan Exercises Options, Sells Shares

What Happened

Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), exercised stock options and sold shares in early May 2026. On May 5 she exercised 50,000 option shares at $7.08 each (cost $354,000) and sold 50,000 shares in the open market for total proceeds reported as $1,928,400. Separately, on May 4 she sold 5,230 shares in the open market for $163,663. The filing also reports a related derivative disposition of 50,000 shares (reported at $0.00) tied to the option conversion/settlement.

Key Details

Transaction dates: May 4, 2026 (sale of 5,230 shares); May 5, 2026 (exercise of 50,000 options and sale of 50,000 shares; derivative disposition of 50,000).
Prices and values reported:
- May 4 sale: 5,230 shares at an average $31.29 — proceeds $163,663 (sales ranged $30.72–$31.66). (F2)
- May 5 exercise: 50,000 shares acquired at $7.08 — cost $354,000.
- May 5 sale: 50,000 shares at an average $38.57 — proceeds $1,928,400 (sales ranged $38.00–$39.96). (F3)
- Derivative disposition: 50,000 at $0.00 (reported as disposition of derivative interest).
Total gross proceeds from the two reported sales ≈ $2,092,063; exercise cost reported $354,000. (Does not account for taxes, fees or share withholding.)
Footnotes:
- F1: The sales were effected under a Rule 10b5‑1 trading plan adopted Dec 26, 2025.
- F4: The exercised options vest monthly (1/48th) beginning Sept 17, 2023, subject to continued service.
Shares owned following the reported transactions: not specified in the information provided in this summary.
Filing timeliness: Form 4 was filed May 5, 2026 for transactions dated May 4–5, 2026 (filed next day).

Context

The filing shows an option exercise (code M) and same‑day sale of the resulting shares, which is a common pattern when insiders exercise stock options and sell shares immediately to cover exercise cost or to monetize gains. The May 4 sale was executed under a pre-established 10b5‑1 plan, which typically sets automated rules for timing and size of sales. This report is factual disclosure of transactions; it does not state the insider’s motives.

Form 4

Period: 2026-05-04

CMO

Transactions

Sale
Common Stock
[F1][F2]
2026-05-04$31.29/sh−5,230$163,663→ 4,367 total
Exercise/Conversion
Common Stock
2026-05-05$7.08/sh+50,000$354,000→ 54,367 total
Sale
Common Stock
[F1][F3]
2026-05-05$38.57/sh−50,000$1,928,400→ 4,367 total
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-05-05−50,000→ 75,000 total
Exercise: $7.08Exp: 2033-08-17→ Common Stock (50,000 underlying)

Footnotes (4)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
[F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

Signature

John R. Moore Attorney-in-Fact for Donovan Joanne M.|2026-05-04

2 files